UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

~~August~~September 2413, 2010 (Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

Michigan		1-31773		38-2505723
(State or other jurisdiction of incorporation)		(Commission file number)		(I.R.S. employer identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 35.02. ~~Unregistered~~Departure ~~Sales~~of Directors or Certain Officers; Election of ~~Equity~~Directors; ~~Securities~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As(d) On ofSeptember ~~August 24~~14, 2010, ~~registrant~~the ~~issued~~Board ~~544,000~~appointed ~~shares~~Eddie ofR. ~~common~~Munson ~~stock~~ to ~~Sun~~serve ~~Pharma~~on ~~Global,~~its ~~Inc.~~Board ~~(“Sun~~of ~~Global”)~~Directors asfor a ~~result~~term ofending at the ~~conversion~~2011 byAnnual ~~Sun~~Meeting ~~Global~~ of ~~544,000~~Shareholders ~~shares~~and ofthe ~~Series~~election Band ~~Preferred~~qualification ~~Stock. 544,000 shares~~ of ~~Series~~his Bsuccessor, ~~Preferred~~as ~~Stock~~set ~~were~~forth ~~originally issued to Sun Global on August 13, 2007~~ in ~~connection with~~ the ~~transfer~~attached ofpress ~~one~~release ~~product~~incorporated onherein ~~such~~by ~~date pursuant to registrant’s products agreement with Sun Global dated November 21, 2002~~reference.

The ~~Series~~Board Bhas ~~Preferred~~determined ~~Stock~~that ~~may~~Mr. beMunson ~~converted~~is ~~into~~independent ~~common~~within ~~stock~~the onmeaning aof ~~one-for-one~~Sections ~~basis~~803A ~~after~~and ~~three~~803B ~~years~~of ~~from~~the NYSE Amex Company Guide (the ~~date~~“Guide”) ofand ~~issuance~~that orhe ~~following~~satisfies the other requirements of a ~~person~~member ~~(other~~serving ~~than~~on ~~Sun~~the ~~Pharmaceutical~~audit ~~Industries~~committee ~~Limited~~as ~~and~~set ~~its~~forth ~~affiliates)~~in ~~acquiring~~Section ~~control~~803B of ~~registrant~~the Guide. In addition to his appointment to the Audit Committee, Mr. Munson was also appointed to the Independent Committee of the Board. In connection with his joining the Board, the Company has entered into an Indemnification Agreement with Mr. Munson.

~~The~~On ~~common~~September ~~stock~~14, ~~was~~2010, ~~issued~~the ~~pursuant~~Board toalso anadopted ~~exemption~~and ~~from~~implemented ~~registration~~a ~~under~~new ~~Section~~compensation ~~4(2)~~arrangement offor ~~the~~its ~~Securities~~outside ~~Act~~directors. The ofnew ~~1933~~compensation arrangement for such directors, including Mr. Munson, is as follows:

Annual Fees (payable in arrears quarterly):	$	18,000

Attendance at regularly scheduled Board meetings (in person or by telephone):	$	3,000

Attendance at regularly scheduled Committee meetings (in person or by telephone):	$	2,500

(However, no additional fees will be paid for Committee meetings if the Committee meets on the same day as the Board meeting.)

Restricted Stock Grants (under the 2008 Equity Participation Plan): 5,000 shares annually which vest at the end of each term to which the director has been appointed or elected (the director must be a director on the vesting date); notwithstanding the above, the granted shares shall vest upon the death or disability of the director.

All directors are also entitled to reimbursement for reasonable travel and lodging expenses incurred in attending meetings.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on September 13, 2010.

At the Annual Meeting, the two nominees for election as directors for the term ending at the 2013 Annual Meeting, and until their successors are elected and qualified, received the following votes:

Name	For		Against		Abstain

Timothy S. Manney		32,174,574		1,401,237		27,571
Sudhir V. Valia		30,513,565		3,060,746		29,071

Item 9.01. Financial Statements and Exhibits.

Exhibits.

Exhibit No.

Description

99.1	Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated September 15, 2010, announcing the appointment of a new director.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Date:	August 30, 2010	By:	/s/ Jitendra N. Doshi
Date: September 15, 2010	By:	/s/ Jitendra N. Doshi
			Jitendra N. Doshi
	Jitendra N. Doshi Chief Executive Officer
			Chief Executive Officer

Exhibit Index

99.1	Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated September 15, 2010 announcing the appointment of a new director.

Filing Compare · CARACO PHARMACEUTICAL LABORATORIES LTD